Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET
Company Participants
Eric McIntyre - Head of Investor Relations
Frank Watanabe - President & Chief Executive Officer
Patrick Burnett - Chief Medical Officer
Ken Lock - Chief Commercial Officer
Scott Burrows - Chief Financial Officer
Conference Call Participants
Vikram Purohit - Morgan Stanley
Seamus Fernandez - Guggenheim
Ken Cacciatore - Cowen
Greg Fraser - Truist
Louise Chen - Cantor
Rohit Bhasin - Needham & Company
Uy Ear - Mizuho Group
Operator
Ladies and gentlemen, thank you for standing by. And welcome to Arcutis Biotherapeutics, Inc. Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference is being recorded.
I will now hand the conference over to your speaker host, Eric McIntyre, Head of Investor Relations. Please go ahead.
Eric McIntyre
Thank you, Olivia. Good afternoon, everyone, and thank you for joining Arcutis' fourth quarter and full year 2022 earnings call. Slides are available on the Investors section of our website.
On today's call, we have Frank Watanabe, President and CEO; Scott Burrows, Chief Financial Officer; Ken Lock, Chief Commercial Officer; and Patrick Burnett, Chief Medical Officer.
During this call, I'd remind everyone that we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. We encourage you to review their information disclosed in our latest SEC filings.
With that, I'll hand the call to Frank.
Frank Watanabe
Thanks, Eric. So I'm on Slide 5 in the deck, which is on our website, if you folks haven't downloaded yet. So 2022 was really a year of exceptional execution for Arcutis, and it really set us up for great success in 2023 and beyond. Just to recap, we had four successful pivotal Phase 3 trials readout, we had on-time approval for ZORYVE and plaque psoriasis, we raised over $300 million to secure a strong balance sheet to support our continued commercialization and advancing of our pipeline, and we continue to progress in building our pipeline.
On Slide 6, we're making steady progress towards our vision of building one of the biotechnologies leading dermatology companies, some highlights from Q4 and other recent developments. With ZORYVE, we've got an innovative product that's really well positioned for long-term success with clinically meaningful benefits over alternative treatments. We're seeing very encouraging script growth as physicians gain positive real-world experience with ZORYVE.